DES Breast Cancer Lawsuit Filed Over Pregnancy Drug

A Boston woman is suing drug makers who manufactured the discontinued pregnancy drug DES (diethylstilbestrol), alleging that the drug her mother took while she was pregnant has caused her to suffer breast cancer as an adult. 

The complaint was filed by Arline MacCormack, and is one of more than 50 similar lawsuits brought by women nationwide who say they are suffering DES side effects because their mothers took the drug while pregnant.

The use of DES was discontinued in the 1970s due to health concerns, after more than 30 years on the market.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Thousands of women have filed DES lawsuits, but most have been settled out-of-court. MacCormack’s lawsuit stands out because of the breast cancer claims. Most DES side effects lawsuits have focused on vaginal cancer.

Some studies have suggested that DES doubles the risk of breast cancer in daughters of former DES users. Compared to the usual 1 in 55 risk of breast cancer in most women, DES daughters over the age of 40 may have a 1 in 25 risk.

There are 14 drug makers named in MacCormack’s DES breast cancer lawsuit, including Bristol-Myers Squibb and Eli Lilly.

DES (diethylstilbestrol) was a synthetic estrogen given to women as pills, topical creams and in other forms. It was in use from the 1940s until the 1971 DES recall and an estimated 4 million people are suspected to have been exposed to it in utero before use was discontinued.

DES was removed from the market in 1971, after studies found that it was ineffective and appeared to be linked to vaginal cancer. However, for several decades, women were given the drug during pregnancy to prevent complications.

Grown daughters of those women are now showing increased rates of breast cancer, infertility and other health problems, studies suggest.

The estimated 2 million men who were born to mothers using DES show some signs of increased risk of testicular problems and cysts, but at nowhere near the rate of problems suffered by women exposed to DES, who are now in their 40s or older.

The side effects of DES appear to be manifesting in granddaughters of users as well, with increased rates of late onset of menstruation and irregular menstrual cycles.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Indicates Recalled Tissue Marker Migrated After It Failed To Absorb, Resulting in Severe Pain and Surgical Removal
BioZorb Lawsuit Indicates Recalled Tissue Marker Migrated After It Failed To Absorb, Resulting in Severe Pain and Surgical Removal (Posted yesterday)

Days after the FDA announced a BioZorb recall, an Arkansas woman has filed a lawsuit, indicating that her BioZorb tissue marker migrated out of position, causing pain and disfigurement, instead of harmlessly absorbing into the body as advertised.

Judge Outlines Suboxone Tooth Decay Lawsuit Census Requirements
Judge Outlines Suboxone Tooth Decay Lawsuit Census Requirements (Posted 2 days ago)

To help the parties identify Suboxone lawsuits that can be used as representative samples in early bellwether trials, the federal judge presiding over the litigation has directed the parties to conduct a census of all tooth decay claims.